Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Navari

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|October 11, 2016
Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomitingR Navari
Bone Marrow Transplantation|November 11, 1999
A prisoner with chronic myeloid leukemiaR Navari, J Horner Catt, M Siegler
Cancer|August 15, 1996
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinomaA A Miller, A Lipton, I C Henderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study GroupR Navari, D Gandara, P Hesketh, et al.
International Journal of Oncology|March 13, 2003
Methylation of TFPI-2 gene is not the sole cause of its silencingChilukuri N Rao, Takehiko Segawa, Jason R Navari, et al.
Cancer Research|October 7, 2004
Proinvasive properties of ovarian cancer ascites-derived membrane vesiclesLaura E Graves, Edgardo V Ariztia, Jason R Navari, et al.
Cancer Investigation|January 1, 1997
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study GroupT M Beck, M York, A Chang, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 21, 2023
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agentsJørn Herrstedt, L Celio, P J Hesketh, et al.
Bone Marrow Transplantation|April 1, 1987
Treatment of marrow graft recipients with thymopentinR P Witherspoon, R Navari, R Storb, et al.
Archives of Internal Medicine|September 12, 1994
Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline aloneR Gucalp, R Theriault, I Gill, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Drugs of Today (Barcelona, Spain : 1998)|October 11, 2016
Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomitingR Navari
Bone Marrow Transplantation|November 11, 1999
A prisoner with chronic myeloid leukemiaR Navari, J Horner Catt, M Siegler
Cancer|August 15, 1996
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinomaA A Miller, A Lipton, I C Henderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study GroupR Navari, D Gandara, P Hesketh, et al.
International Journal of Oncology|March 13, 2003
Methylation of TFPI-2 gene is not the sole cause of its silencingChilukuri N Rao, Takehiko Segawa, Jason R Navari, et al.
Cancer Research|October 7, 2004
Proinvasive properties of ovarian cancer ascites-derived membrane vesiclesLaura E Graves, Edgardo V Ariztia, Jason R Navari, et al.
Cancer Investigation|January 1, 1997
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study GroupT M Beck, M York, A Chang, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 21, 2023
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agentsJørn Herrstedt, L Celio, P J Hesketh, et al.
Bone Marrow Transplantation|April 1, 1987
Treatment of marrow graft recipients with thymopentinR P Witherspoon, R Navari, R Storb, et al.
Archives of Internal Medicine|September 12, 1994
Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline aloneR Gucalp, R Theriault, I Gill, et al.
Pageof 2